Control first, tolerance second: biologics as enablers of allergen immunotherapy in severe allergic asthma.

Xolair (omalizumab) - Roche, Novartis

Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen

Dupixent (dupilumab) - Sanofi, Regeneron

http://www.ncbi.nlm.nih.gov/pubmed/42781325

A Hoheisel; B C Frye; B Jentzsch; D Stolz; I Cherrez-Ojeda; J A Alvarado Castillo; K Gashynova; S Fähndrich; S Müller

Sep 25, 2026